U.S. Supreme Court Roundly Rejects Case Concerning the Medication, Mifepristone

The U.S. Supreme Court has voted 9-0 against a lawsuit by doctors and medical associations opposed to abortion, ruling that the plaintiffs do not have the necessary legal standing to challenge the U.S. Food and Drug Administration’s (FDA) actions regarding the regulation of mifepristone.

The status quo is maintained concerning the regulation and availability of mifepristone, the first of two medicines in the medication abortion regimen approved by the FDA as safe and effective through 70 days’ gestation.

Gynuity Health Projects welcomes the Supreme Court decision, but we remain vigilant. Political threats of this type deny reproductive freedom. The evidence and data that we and other scientists work hard to produce continue to be important counterweights to irresponsible pseudoscience.

Gynuity has a significant interest in evidence-based reproductive health services and proactively engages in designing and implementing research to change policy, increase access to abortion care, and improve services. To date, our efforts to broaden access to medication abortion and remove regulatory restrictions on mifepristone in the U.S. have included:

• Completing seminal clinical research demonstrating that medication abortion using a combined mifepristone and misoprostol regimen is safe, effective, and desirable to patients.
• Providing data to support the FDA’s 2016 decision to expand outpatient medication abortion through 70 days of pregnancy.
• Providing data to support the FDA’s 2021 decision to remove the in-person dispensing requirement for mifepristone, allowing counseling and prescription through telemedicine appointments and mailing of the abortion medication.

Our work is far from over, and your urgent support is needed now more than ever. Please donate today.